Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
Clinical trial Global

Tirzepatide: registry results posted for a completed Phase 1 obesity study in children aged 6 to 11

Eli Lilly and Company, the sponsor, has posted results on the ClinicalTrials.gov registry for a completed Phase 1 safety, tolerability and pharmacokinetic study of tirzepatide in children aged 6 to 11 years with obesity, submitted on 15 July 2025 and posted on 26 August 2025.

Neutral laboratory bench with sealed glass vials and a notebook, no people and no branding

What is Tirzepatide?

Tirzepatide is a 39-amino-acid peptide built on the GIP sequence that activates both the GIP and GLP-1 receptors; a C20 fatty diacid attached to lysine 20 binds albumin and gives a half-life of about five days.

Read the full guide →

In 30 seconds

  • The registry record for the Eli Lilly Phase 1 study of tirzepatide in children aged 6 to 11 years with obesity is listed as completed, with results now posted.
  • The study was randomized, parallel and double masked (participants and investigators), with cohorts split by screening body weight, each cohort including a placebo comparator.
  • Its stated measures were the percentage of participants with adverse events and how the body processed the study drug, not weight or BMI change.

Why it matters

This registry record for tirzepatide covers a very young group: children aged 6 to 11 years with obesity. The record describes the main purpose of the study as evaluating the safety and tolerability of tirzepatide in pediatric participants with obesity, with blood tests to investigate how the body processes the study drug in these participants. The registry lists the primary purpose of the study as basic science, so the posted record is about early safety and drug handling rather than about how much weight or BMI changed.

The details

  • Official title: a safety, tolerability and pharmacokinetic study of tirzepatide for the treatment of pediatric participants (6 years to 11 years) with obesity.
  • Design: interventional, Phase 1, randomized, parallel assignment, double masking (participant and investigator), primary purpose listed as basic science.
  • Cohorts were defined by screening body weight, and each cohort included a placebo comparator group given placebo subcutaneously once weekly during Weeks 1 to 8.
  • For each participant, the record says the study was to last about approximately 13 weeks excluding the screening period.
  • Stated measures: the percentage of participants with one or more treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), plus the area under the concentration versus time curve from time 0 to the end of the dosing interval (AUC0-tau) of tirzepatide and its maximum concentration (Cmax).
  • To take part, participants had to have a body mass index at or above the 95th percentile for age and sex, and to have failed to achieve adequate weight loss through lifestyle modification in the investigator's opinion.
  • Female participants had to be determined as prepubertal Tanner Stage 1.
  • Exclusions included confirmed type 1 or type 2 diabetes mellitus, acute or chronic pancreatitis or a history of acute idiopathic pancreatitis, obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity, previous weight loss surgery such as gastric bypass, and a change in body weight above 5 kg (11 lbs) within 90 days before screening.
  • Listed study locations were in the United States, including the Atlanta Center of Medical Research in Atlanta, Georgia.

What it does not change

This is a posted result on a clinical trial registry, not an approval or a label change for any age group. The record is a Phase 1 study whose primary purpose is listed as basic science, with safety, tolerability and drug concentration measures, so it does not establish how effective tirzepatide is in children. The study population was narrow by design: children aged 6 to 11 years, female participants prepubertal Tanner Stage 1, with confirmed type 1 or type 2 diabetes mellitus and several gastrointestinal and endocrine conditions excluded. Results from this record therefore say nothing about older children, adolescents or adults, and nothing about the groups the protocol excluded.

What's next

The record itself does not describe any further study step. It states that results were first submitted on 15 July 2025, with the quality control date of 22 August 2025 and posting on 26 August 2025, and the study status was verified in August 2025 and listed as completed, with 7 February 2023 and 16 January 2025 given as actual dates. The record also points readers to its own Reported Adverse Events section for the summary of TEAEs, SAEs and other non serious adverse events, regardless of causality.

What we don't know yet

The registry text used here announces which measures were collected but does not give their values: there are no adverse event percentages for any tirzepatide cohort next to its placebo comparator, and no drug concentration figures. No weight change or BMI change outcome appears in this record at all, so any figure of that kind circulating about this study cannot be checked against it. The record also does not say what the sponsor concluded, whether a later phase is planned in this age group, or how the cohorts compared with each other.

Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.

Source documents

This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.